Journal of Antimicrobial Chemotherapy (1999) 44, Topic A, 31-36
© 1999 The British Society for Antimicrobial Chemotherapy
Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci
Hôpital Bichat-Claude Bernard, Médecine Interne, 10è étage, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
Infection with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus faecium (VREF) increases the risk of mortality and results in prolonged hospitalization and high utilization of costly treatment modalities. Measures to prevent the spread of MRSA (and possibly VREF) include patient isolation and decontamination, hygiene measures, ward closure, and screening of patients and staff for carriage. In seriously ill patients, the increased use of vancomycin for the treatment of MRSA can lead to the emergence of VREF colonization/infection. Quinupristin/dalfopristin is effective in the treatment of MRSA infections, including nosocomial pneumonia, skin and soft tissue infection, and septicaemia. In the treatment of nosocomial pneumonia, clinical success rates were equivalent between quinupristin/dalfopristin and vancomycin. In the context of a hospital policy which emphasizes effective hygiene measures and the prudent use of antibacterials, quinupristin/dalfopristin is an effective antimicrobial that can help to control the high costs associated with multiresistant MRSA and VREF infections.
* Tel: +33-1-40-25-80-80; Fax: +33-1-40-25-88-45.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. D Mauldin, C. D Salgado, V. L Durkalski, and J. A Bosso Nosocomial Infections Due to Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus: Relationships with Antibiotic Use and Cost Drivers Ann. Pharmacother., March 1, 2008; 42(3): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Bosso and P. D. Mauldin Using Interrupted Time Series Analysis To Assess Associations of Fluoroquinolone Formulary Changes with Susceptibility of Gram-Negative Pathogens and Isolation Rates of Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2106 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S McKinnon, S. V Sorensen, L. Z Liu, and K. M. Itani Impact of Linezolid on Economic Outcomes and Determinants of Cost in a Clinical Trial Evaluating Patients with MRSA Complicated Skin and Soft-Tissue Infections Ann. Pharmacother., June 1, 2006; 40(6): 1017 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fang and G. Hedin Use of Cefoxitin-Based Selective Broth for Improved Detection of Methicillin-Resistant Staphylococcus aureus J. Clin. Microbiol., February 1, 2006; 44(2): 592 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maisch, C. Bosl, R.-M. Szeimies, N. Lehn, and C. Abels Photodynamic Effects of Novel XF Porphyrin Derivatives on Prokaryotic and Eukaryotic Cells Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1542 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J Kopp, D. E Nix, and E. P Armstrong Clinical and Economic Analysis of Methicillin-Susceptible and -Resistant Staphylococcus aureus Infections Ann. Pharmacother., September 1, 2004; 38(9): 1377 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tacconelli, L. Venkataraman, P. C. De Girolami, and E. M. C. D'Agata Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains J. Antimicrob. Chemother., March 1, 2004; 53(3): 474 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cepeda, T. Whitehouse, B. Cooper, J. Hails, K. Jones, F. Kwaku, L. Taylor, S. Hayman, S. Shaw, C. Kibbler, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study J. Antimicrob. Chemother., February 1, 2004; 53(2): 345 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Safdar, L. Narans, B. Gordon, and D. G. Maki Comparison of Culture Screening Methods for Detection of Nasal Carriage of Methicillin-Resistant Staphylococcus aureus: a Prospective Study Comparing 32 Methods J. Clin. Microbiol., July 1, 2003; 41(7): 3163 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Butaye, L. A. Devriese, and F. Haesebrouck Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria Clin. Microbiol. Rev., April 1, 2003; 16(2): 175 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. John, C. Pletch, and Z. Hussain In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci J. Antimicrob. Chemother., December 1, 2002; 50(6): 933 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Steinstraesser, B. F. Tack, A. J. Waring, T. Hong, L. M. Boo, M.-H. Fan, D. I. Remick, G. L. Su, R. I. Lehrer, and S. C. Wang Activity of Novispirin G10 against Pseudomonas aeruginosa In Vitro and in Infected Burns Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1837 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Dailey, C. L. Dileto-Fang, L. V. Buchanan, M. P. Oramas-Shirey, D. H. Batts, C. W. Ford, and J. K. Gibson Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2304 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.M. AL-HADDAD, E.E. UDO, E.M. MOKADAS, S.C. SANYAL, and W.B. GRUBB Persistence of a clone of methicillin-resistant Staphylococcus aureus in a burns unit J. Med. Microbiol., June 1, 2001; 50(6): 558 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Drew, J. R. Perfect, L. Srinath, E. Kurkimilis, M. Dowzicky, G. H. Talbot, and for the Synercid Emergency-Use Study Group Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy J. Antimicrob. Chemother., November 1, 2000; 46(5): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Francis, D. Joh, C. Bellinger-Kawahara, M. J. Hawkinson, T. F. Purchio, and P. R. Contag Monitoring Bioluminescent Staphylococcus aureus Infections in Living Mice Using a Novel luxABCDE Construct Infect. Immun., June 1, 2000; 68(6): 3594 - 3600. [Abstract] [Full Text] [PDF]
|
|